ATNF Share Price Performance
US$3.00
1.24 (70.60%)
Price US$3.00
Share PriceUS$3.00
ATNF Community Narratives
There are no narratives available yet.
Recent ATNF News & Updates
No updates
180 Life Sciences Corp. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.11
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 26.3%
180 Life Sciences Corp. Competitors
About ATNF
- Founded
- n/a
- Employees
- 4
- CEO
- WebsiteView website
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
U.S. Market Performance
- 7 Days: 2.3%
- 3 Months: 12.9%
- 1 Year: 20.2%
- Year to Date: 8.3%
The market is up 2.3% over the last week, with the Information Technology sector leading the way, up 4.1%. The market is up 20% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading